ADVA introduces multi-layer cell site gateway to maximize 5G efficiency
5.9.2019 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its FSP 150-XG118Pro, a cell site gateway device specifically designed to meet the challenges of 5G. Ideal for deployment at radio base stations, the ADVA FSP 150-XG118Pro meets urgent demand for ultra-reliable low-latency communications (URLLC) in 5G mobile networks and supports a smooth transition from 1Gbit/s to 10Gbit/s services. The solution also features a temperature-hardened design and precise synchronization capabilities. What’s more, with its industry-leading demarcation technology and pluggable high-performance server, the FSP 150-XG118Pro enables virtual network functions (VNFs) to be hosted at the edge of the network and gives communication service providers (CSPs) and mobile wholesale operators a risk-free route to network functions virtualization (NFV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005062/en/
The ADVA FSP 150-XG118Pro is the ultimate tool for rapid 5G rollouts over existing LTE infrastructure (Photo: Business Wire)
“Our FSP 150-XG118Pro brings high-capacity demarcation and edge aggregation to the radio base station without exceeding strict requirements for space, power and cost. It really is the ultimate tool for rapid 5G rollouts over existing LTE infrastructure,” said Richard Strike, director, product line management, ADVA. “Our FSP 150-XG118Pro empowers mobile network operators (MNOs) to respond to soaring bandwidth needs with 10Gbit/s bandwidth at the radio base station. They can also cater for new URLLC applications that demand data to be processed right where it’s created. And, as the solution has been built with our Oscilloquartz team of network synchronization specialists, it delivers the accurate and stable timing that’s so crucial for 5G applications.”
The ADVA FSP 150-XG118Pro has been specifically engineered to support a seamless, cost-efficient transition from LTE mobile networks to 5G. With multi-layer demarcation and precise synchronization delivery, the cell site gateway device meets all current mobile network requirements, and its 10Gbit/s capacity enables MNOs to utilize the full 5G spectrum. Its open software-defined networking (SDN) control supports automated network slicing and its pluggable server allows it to be upgraded in-service for edge hosting of VNFs. The ADVA FSP 150-XG118Pro’s capacity and edge hosting capabilities also enable enterprises to unlock the potential of the industrial IoT (IIoT). This makes the solution ideal for a wide range of IIoT business cases that require ultra-low latency and massive machine connectivity.
“This new member of our hugely successful and widely deployed FSP 150 family opens the door to a world of new opportunities. It tears down the entry barriers and provides CSPs and businesses with a risk-free route to all the advantages of virtualization,” commented Ulrich Kohn, director, technical marketing, ADVA. “Featuring our award-winning, field-proven Ensemble Connector NFV hosting software, our FSP 150-XG118Pro enables enterprises to seize the full business potential of the IIoT. It supports big data analytics at the very edge of the network, saving significant bandwidth and improving performance. Now businesses can benefit from our vast experience with migrating centrally hosted network functions to the edge. Our customers can focus on revenue-generating services while we handle complex network integration and testing and ensure superb levels of performance.”
Watch this video for more information on the FSP 150-XG118Pro: http://adva.li/fsp-150-xg118pro-video.
Additional details can also be found in these slides: http://adva.li/fsp-150-xg118pro-slides.
A supporting solution brief can be downloaded here: http://adva.li/connecting-5g-new-radios.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005062/en/
Contact information
For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com
For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom